SAM
AIMT

Sectoral Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Sectoral Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-982,133
Closed -$13.3M – 81
2016
Q1 		$13.3M Hold
982,133
– – 0.64% 41
2015
Q4 		$18.1M Buy
982,133
+189,495
+24% +$3.51M 0.77% 36
2015
Q3 		$20.1M Buy
+792,638
New +$18.5M 0.92% 29

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sectoral Asset Management's AIMT Position: Q2 2016 in Review

Sectoral Asset Management sold out of Aimmune Therapeutics (AIMT) in Q2 2016, closing a stake of 982,133 shares — an estimated $13.3M sold.

Sectoral Asset Management first reported a position in AIMT in Q3 2015 and held it in 3 quarters. The position peaked at $20.1M in Q3 2015. 74 funds tracked by Wall St. Rank hold AIMT as of Q2 2016.

  • Sectoral Asset Management reported no remaining Aimmune Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Sectoral Asset Management sold 982,133 Aimmune Therapeutics shares in Q2 2016, an estimated $13.3M.
  • Sectoral Asset Management first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 3 quarters.
  • Sectoral Asset Management's Aimmune Therapeutics position peaked at $20.1M in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2016.

Based on Sectoral Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.